Developer docs
API playgroundTry for free, no card

Search company profiles

Adragos Pharma

Full company profile

uuid0007o1x

Namestring
Adragos Pharma
Legal namestring
Adragos Pharma GmbH
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Adragos Pharma is a Germany-headquartered global contract development and manufacturing organization (CDMO) specializing in sterile injectables, oral solid dosage forms, semi-solids, and non-sterile liquids. Founded in 2020 as part of the Plange Group, the company has built a seven-facility network spanning Germany, France, Norway, Switzerland, Greece, and Japan, with capabilities spanning prefilled syringe filling (150 million units annual capacity), vial filling (6 million units), tablet production (2 billion units), Blow-Fill-Seal IV bag technology, lyophilized vial manufacturing, and high-potency active pharmaceutical ingredient (HPAPI) handling. Each facility operates under multi-jurisdictional regulatory certifications including EU GMP, U.S. FDA, Japan PMDA, and Brazil ANVISA, enabling Adragos to serve as a primary or secondary supply source across the three largest pharmaceutical markets simultaneously.

The company's technology stack is rooted in acquired industrial assets rather than proprietary R&D, with capabilities inherited from the Lamda Labs, Sanofi Kawagoe, Fresenius Kabi Halden, Baccinex, and Sanofi Maisons-Alfort facility transactions completed between 2023 and 2026. Technical differentiation is concentrated in complex sterile formats (BFS IV bags, prefilled syringes, lyophilized vials) and HPAPI handling, which command premium pricing relative to commodity oral solid dose manufacturing. Adragos's portfolio is positioned to capture both branded and generic injectable supply contracts as big-pharma players continue divesting captive manufacturing capacity.

Adragos operates a project-based B2B revenue model typical of mid-tier CDMOs, monetizing through long-term commercial supply agreements, technology transfer fees, and development contracts. Anchor customers include Fresenius Kabi (via a multi-year supply agreement tied to the Halden acquisition), Towa Pharmaceutical (Japan), Colonis Pharma, and emerging biotech clients such as Igyxos and Roma Pharmaceuticals. The company is privately held under the Plange Group with FSN Capital Partners as institutional investor. Go-to-market emphasizes geographic proximity to regional pharma clusters, regulatory multi-jurisdictional coverage, and capacity for both large commercial-scale production and smaller specialty batches.

Short descriptiontext

Adragos Pharma is a Munich-headquartered global CDMO operating seven sterile injectable, oral solid, and specialty manufacturing facilities across Europe and Japan. It serves branded pharma, generic manufacturers, and biotechs with prefilled syringes, vials, BFS IV bags, and HPAPI capabilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMunich, Germany
HQ citystring
Munich
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical contract manufacturing, drug development services, sterile injectables manufacturing, aseptic fill-finish services, lyophilization manufacturing services
Industry5 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Development Services
TypeProfessional Services
Description

Full spectrum of drug development services including formulation development, analytical development, clinical development, and HPAPI expertise. Services provided from early-stage development through scale-up to commercial production.

adragos-pharma.com
2Clinical Manufacturing Services
TypeProfessional Services
Description

GMP-compliant clinical trial manufacturing including preclinical material preparation, aseptic filling, and lyophilization services for clinical supply.

adragos-pharma.com
3Commercial Manufacturing Services
TypeManaged Services
Description

Large-scale manufacturing of sterile liquids (prefilled syringes, vials, ampoules, IV bags), non-sterile liquids, semi-solids, oral solids, and suppositories for commercial supply.

adragos-pharma.com
4Integrated Services
TypeProfessional Services
Description

Additional services including visual inspection, pharmaceutical packaging, controlled drugs handling, supply chain planning, drug stability testing, cold chain management, and regulatory services.

adragos-pharma.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D
Pricing details1 tier
1Project-based pricing tailored to client specifications
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is determined based on specific project requirements including drug development scope, manufacturing scale, regulatory requirements, and timeline needs. No standard pricing tiers publicly available.

adragos-pharma.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Adragos Pharma is a global Contract Development and Manufacturing Organization (CDMO) providing end-to-end pharmaceutical services spanning drug development, clinical manufacturing, and commercial manufacturing. Its offering covers formulation, analytical, and clinical development including HPAPI expertise, GMP-compliant clinical trial manufacturing, and large-scale commercial production of sterile liquids (prefilled syringes, vials, ampoules, IV bags), non-sterile liquids, oral solids, semi-solids, and suppositories, complemented by visual inspection, packaging, cold chain, regulatory, and out-licensing services across seven facilities in Europe and Japan.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 150 million prefilled syringes per year capacity at Maisons-Alfort facility
+4 more records
Product overview1 text field

Adragos Pharma is a global Contract Development and Manufacturing Organization (CDMO) headquartered in Munich, Germany, providing comprehensive end-to-end CDMO services for pharmaceutical and biotech companies. Their integrated offering spans from drug development (formulation, analytical, clinical development, HPAPI expertise) through clinical manufacturing (preclinical material, aseptic filling, lyophilisation) to commercial manufacturing. The commercial manufacturing portfolio includes sterile liquids (prefilled syringes, vials, ampoules, IV bags), non-sterile liquids (oral solutions, drops, suspensions), semi-solids (creams, ointments, gels), oral solids, and suppositories. Supporting services include visual inspection, pharmaceutical packaging, controlled drugs handling, supply chain planning, drug stability testing, cold chain management, regulatory services, and out licensing. With seven global manufacturing and development facilities across Europe (Athens, Halden, Jura, Livron, Leipzig, Maisons-Alfort) and Japan (Kawagoe), plus regional offices in Munich and Tokyo, Adragos serves clients throughout Europe, Japan, and North America.

Product and service17 records
1Drug Development Services
CategoryDrug Development Services
Description

Comprehensive pharmaceutical CDMO development services covering formulation development, analytical development, clinical development, and HPAPI expertise for both small and large molecules. Targeted at pharmaceutical and biotech companies seeking outsourced development through clinical phases and on to commercial manufacturing.

2Clinical Manufacturing Services
CategoryClinical Manufacturing Services
Description

End-to-end clinical manufacturing services from feasibility studies and pre-clinical material preparation through GMP-compliant production, including aseptic filling and lyophilisation. Serves biotech and pharmaceutical clients preparing clinical trial supplies for sterile and lyophilised products.

3Commercial Manufacturing Services
CategoryCommercial Manufacturing Services
Description

Large-scale commercial manufacturing delivered across five European facilities and one Japanese facility, covering sterile and non-sterile liquids, oral solids, semi-solids, and biologicals. Serves pharmaceutical companies requiring commercial supply of finished dosage forms.

4Sterile Injectables Manufacturing - Prefilled Syringes and Vials
CategorySterile Liquids Manufacturing
Description

High-speed aseptic filling of prefilled syringes and liquid/lyophilised vials at the Maisons-Alfort facility in France, with up to 150 million prefilled syringe units per year capacity and up to 6 million vials per year including lyophilised formats. Serves pharma clients requiring large-scale European sterile injectables supply.

5IV Bags and Plastic Ampoules (Blow-Fill-Seal) Manufacturing
CategorySterile Liquids Manufacturing
Description

Manufacture of sterile IV bags from 50 mL to 5,000 mL and plastic ampoules using Blow-Fill-Seal (BFS) technology at the Halden facility in Norway, with IV bag batch sizes up to 15,000 L. Targets pharmaceutical clients needing high-volume sterile liquids and parenteral packaging.

6Value-Added Medicines Development with HPAPI Expertise
CategoryDrug Development Services
Description

Specialised pharmaceutical development services at the Athens development centre covering Value-Added Medicines (VAMs), generic, and NCE development with HPAPI capabilities and EU GMP certification for handling controlled substances including clonazepam, phenobarbital, and fentanyl. Serves generic and specialty pharma companies needing differentiated formulations.

7Tablets and Sterile Ampoules Manufacturing (Kawagoe)
CategoryOral Solids Manufacturing
Description

Manufacture of oral solid tablets (up to 2 billion annually) and sterile ampoules (up to 30 million units annually) with integrated visual inspection and packaging services at the Kawagoe facility in Japan, supported by PMDA certification and one of Japan's largest cold storage warehouses. Serves Japanese pharmaceutical clients requiring oral solid and sterile ampoule manufacturing with full service.

8Sterile Liquids Ampoules and Suppositories Manufacturing (Livron)
CategorySterile Liquids Manufacturing
Description

Sterile liquid ampoules and suppository manufacturing with over 100 years of operating experience at the Livron facility in France, handling over 100 molecules with integrated stability studies, narcotics handling, and analytical testing under EU GMP (ANSM, ANSES) and KFDA certification. Serves pharmaceutical clients requiring traditional European sterile ampoule and suppository supply.

9Semi-Solids and Non-Sterile Liquids Manufacturing (Leipzig)
CategorySemi-Solids Manufacturing
Description

Manufacture of semi-solid dosage forms (creams, gels, ointments, healing pastes) and non-sterile liquids (oral solutions, drops, suspensions, emulsions, disinfection products) at the Leipzig facility in Germany, with over 100 years of experience and EU GMP certification for human and veterinary medicinal products under the German Medicines Act.

10Clinical and Commercial Small-Batch Sterile Manufacturing (Jura)
CategorySterile Liquids Manufacturing
Description

GMP-certified clinical and commercial manufacturing of lyophilised and liquid sterile (bio)pharmaceuticals in small batches with no minimum lot size requirement at the Jura facility in Switzerland, supporting production from as little as 200-300 mL of API through commercial supply. Serves biotech, orphan-drug, and specialty pharma clients requiring low-volume lyophilised or liquid sterile production.

11Automated Visual Inspection Services
CategoryQuality Inspection Services
Description

Automated and semi-automatic visual inspection for prefilled syringes (up to 600 syringes/minute) and vials (up to 100 vials/minute) ensuring consistent product quality at scale. Service is integrated with sterile manufacturing across facilities and is also offered for client-supplied product.

12Pharmaceutical Packaging Services
CategoryPackaging Services
Description

Complete primary and secondary pharmaceutical packaging solutions delivered in conjunction with manufacturing across the Adragos network. Supports prefilled syringe assembly, vial packaging, and finished product configuration.

13Controlled Drugs Handling Services
CategorySpecialty Manufacturing Services
Description

Specialised manufacturing and handling services for controlled substances and narcotics at facilities licensed for narcotics such as the Athens site (clonazepam, phenobarbital, fentanyl) and Livron's narcotics handling capability. Supports pharmaceutical clients requiring scheduled-drug production with full regulatory compliance.

14Drug Stability Testing Services
CategoryAnalytical Testing Services
Description

Comprehensive pharmaceutical stability testing services to establish product shelf-life and meet regulatory submission requirements across FDA, EMA, PMDA, and other authorities. Provided as integrated support alongside Adragos manufacturing and analytical development.

15Cold Chain Management Services
CategorySupply Chain Services
Description

Temperature-controlled storage and distribution services for sensitive pharmaceutical products, leveraging cold-storage infrastructure such as the Kawagoe facility's large cold storage warehouse. Supports biotech and pharma products requiring strict temperature control across the supply chain.

16Regulatory Affairs Services
CategoryRegulatory Services
Description

Regulatory affairs support across development, clinical, and commercial stages including eCTD-format documentation, submission preparation, and liaison with multi-regional authorities (FDA, EMA, PMDA, ANSM, Swissmedic, and others). Helps pharma clients navigate multi-market approval pathways.

17Out Licensing Services
CategoryLicensing Services
Description

Licensing-out services for pharmaceutical products and intellectual property developed at Adragos facilities, enabling partners to bring developed products into additional markets through structured licensing arrangements.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Towa Pharmaceutical (東和약품)
Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Adragos Pharma Kawagoe signed a basic agreement for strategic collaboration with Towa Pharmaceutical, strengthening partnership for Japanese pharmaceutical manufacturing.

adragos-pharma.com
2Colonis Pharma
Strategic tierSignificantTypeStrategic or Co-development Partner
Description

Long-standing partnership strengthened between Adragos Pharma and Colonis Pharma for pharmaceutical development and manufacturing collaboration.

adragos-pharma.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European CDMO offering oral solids, semi-solids and sterile liquids across multiple sites; comparable to Adragos' Leipzig, Livron and Maisons-Alfort footprint and similar mid-cap, multi-site profile.

TypeDirect peer
Description

European CDMO focused on sterile injectables, oral solids and semi-solids with multiple manufacturing sites; directly comparable size, geography and service mix to Adragos.

TypeBroad incumbent
Description

Global, multi-modality CDMO incumbent with large sterile injectable and oral solid capacity; competes with Adragos on large-scale biotech outsourcing deals where Adragos is one of many options.

TypeDirect peer
Description

European biopharma CDMO focused on complex biologics, cell and gene therapy and fill-finish — overlapping with Adragos' Athens HPAPI and Halden sterile capabilities for biotech clients.

TypeBroad incumbent
Description

Swiss-listed global CDMO leader in biologics, small molecules and sterile manufacturing; sets the benchmark for scale and capability against which mid-caps like Adragos are benchmarked in RFPs.

6Recipharm
TypeDirect peer
Description

Private European CDMO (EQT-owned) with broad sterile and oral solid capabilities across many sites; competes head-to-head with Adragos in fill-finish, oral solids and semi-solids for European pharma clients.

TypeEmerging player
Description

Smaller European CDMO focused on sterile injectables and lyophilization; recently acquired by Adragos (Nov 2024), illustrating Adragos' M&A appetite and serving as a smaller-scale sterile injectable comparable.

TypeDirect peer
Description

Swiss-listed CDMO covering APIs through finished dosage forms including sterile and oral solids; comparable integrated offering and similar European base of operations.

TypeDirect peer
Description

Family-owned German CDMO specializing in sterile injectables, prefilled syringes and lyophilized vials — directly overlapping with Adragos' Maisons-Alfort and Jura capabilities and targeting the same biotech and specialty-pharma clients.

10Fareva
TypeRegional player
Description

Privately-held French-headquartered CDMO with sterile, semi-solid and oral solid manufacturing across Europe; comparable offering, particularly in France alongside Adragos' Livron and Maisons-Alfort sites.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adragos Pharma

Pharmaceutical Contract Development and Manufacturing (CDMO)adragos-pharma.com

Adragos Pharma is a Munich-headquartered global CDMO operating seven sterile injectable, oral solid, and specialty manufacturing facilities across Europe and Japan. It serves branded pharma, generic manufacturers, and biotechs with prefilled syringes, vials, BFS IV bags, and HPAPI capabilities.

What Adragos Pharma does

Adragos Pharma is a Germany-headquartered global contract development and manufacturing organization (CDMO) specializing in sterile injectables, oral solid dosage forms, semi-solids, and non-sterile liquids. Founded in 2020 as part of the Plange Group, the company has built a seven-facility network spanning Germany, France, Norway, Switzerland, Greece, and Japan, with capabilities spanning prefilled syringe filling (150 million units annual capacity), vial filling (6 million units), tablet production (2 billion units), Blow-Fill-Seal IV bag technology, lyophilized vial manufacturing, and high-potency active pharmaceutical ingredient (HPAPI) handling. Each facility operates under multi-jurisdictional regulatory certifications including EU GMP, U.S. FDA, Japan PMDA, and Brazil ANVISA, enabling Adragos to serve as a primary or secondary supply source across the three largest pharmaceutical markets simultaneously.

The company's technology stack is rooted in acquired industrial assets rather than proprietary R&D, with capabilities inherited from the Lamda Labs, Sanofi Kawagoe, Fresenius Kabi Halden, Baccinex, and Sanofi Maisons-Alfort facility transactions completed between 2023 and 2026. Technical differentiation is concentrated in complex sterile formats (BFS IV bags, prefilled syringes, lyophilized vials) and HPAPI handling, which command premium pricing relative to commodity oral solid dose manufacturing. Adragos's portfolio is positioned to capture both branded and generic injectable supply contracts as big-pharma players continue divesting captive manufacturing capacity.

Adragos operates a project-based B2B revenue model typical of mid-tier CDMOs, monetizing through long-term commercial supply agreements, technology transfer fees, and development contracts. Anchor customers include Fresenius Kabi (via a multi-year supply agreement tied to the Halden acquisition), Towa Pharmaceutical (Japan), Colonis Pharma, and emerging biotech clients such as Igyxos and Roma Pharmaceuticals. The company is privately held under the Plange Group with FSN Capital Partners as institutional investor. Go-to-market emphasizes geographic proximity to regional pharma clusters, regulatory multi-jurisdictional coverage, and capacity for both large commercial-scale production and smaller specialty batches.

Adragos Pharma firmographics

Firmographics
Name
Adragos Pharma
Legal name
Adragos Pharma GmbH
Website
https://adragos-pharma.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
251–500 employees
Short description
Adragos Pharma is a Munich-headquartered global CDMO operating seven sterile injectable, oral solid, and specialty manufacturing facilities across Europe and Japan. It serves branded pharma, generic manufacturers, and biotechs with prefilled syringes, vials, BFS IV bags, and HPAPI capabilities.
Ownership category
akta.pro rank

Adragos Pharma industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics

Keywords

  • Pharmaceutical contract manufacturing
  • Drug development services
  • Sterile injectables manufacturing
  • Aseptic fill-finish services
  • Lyophilization manufacturing services

Where Adragos Pharma is headquartered

Location

Headquarters

HQ city
Munich
HQ country
Germany
HQ region
Europe

Offices9 records

Markets served

Adragos Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D

Revenue model

  1. Contract Development Services: Full spectrum of drug development services including formulation development, analytical development, clinical development, and HPAPI expertise. Services provided from early-stage development through scale-up to commercial production.
  2. Clinical Manufacturing Services: GMP-compliant clinical trial manufacturing including preclinical material preparation, aseptic filling, and lyophilization services for clinical supply.
  3. Commercial Manufacturing Services: Large-scale manufacturing of sterile liquids (prefilled syringes, vials, ampoules, IV bags), non-sterile liquids, semi-solids, oral solids, and suppositories for commercial supply.
  4. Integrated Services: Additional services including visual inspection, pharmaceutical packaging, controlled drugs handling, supply chain planning, drug stability testing, cold chain management, and regulatory services.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based pricing tailored to client specifications

Go-to-market motion1 record

Distribution channels3 records

Marketing channels10 records

Adragos Pharma product offering

Product offering

Core offering

Adragos Pharma is a global Contract Development and Manufacturing Organization (CDMO) providing end-to-end pharmaceutical services spanning drug development, clinical manufacturing, and commercial manufacturing. Its offering covers formulation, analytical, and clinical development including HPAPI expertise, GMP-compliant clinical trial manufacturing, and large-scale commercial production of sterile liquids (prefilled syringes, vials, ampoules, IV bags), non-sterile liquids, oral solids, semi-solids, and suppositories, complemented by visual inspection, packaging, cold chain, regulatory, and out-licensing services across seven facilities in Europe and Japan.

Product overview

Adragos Pharma is a global Contract Development and Manufacturing Organization (CDMO) headquartered in Munich, Germany, providing comprehensive end-to-end CDMO services for pharmaceutical and biotech companies. Their integrated offering spans from drug development (formulation, analytical, clinical development, HPAPI expertise) through clinical manufacturing (preclinical material, aseptic filling, lyophilisation) to commercial manufacturing. The commercial manufacturing portfolio includes sterile liquids (prefilled syringes, vials, ampoules, IV bags), non-sterile liquids (oral solutions, drops, suspensions), semi-solids (creams, ointments, gels), oral solids, and suppositories. Supporting services include visual inspection, pharmaceutical packaging, controlled drugs handling, supply chain planning, drug stability testing, cold chain management, regulatory services, and out licensing. With seven global manufacturing and development facilities across Europe (Athens, Halden, Jura, Livron, Leipzig, Maisons-Alfort) and Japan (Kawagoe), plus regional offices in Munich and Tokyo, Adragos serves clients throughout Europe, Japan, and North America.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug Development Services Comprehensive pharmaceutical CDMO development services covering formulation development, analytical development, clinical development, and HPAPI expertise for both small and large molecules. Targeted at pharmaceutical and biotech companies seeking outsourced development through clinical phases and on to commercial manufacturing.
  • Clinical Manufacturing Services End-to-end clinical manufacturing services from feasibility studies and pre-clinical material preparation through GMP-compliant production, including aseptic filling and lyophilisation. Serves biotech and pharmaceutical clients preparing clinical trial supplies for sterile and lyophilised products.
  • Commercial Manufacturing Services Large-scale commercial manufacturing delivered across five European facilities and one Japanese facility, covering sterile and non-sterile liquids, oral solids, semi-solids, and biologicals. Serves pharmaceutical companies requiring commercial supply of finished dosage forms.
  • Sterile Injectables Manufacturing - Prefilled Syringes and Vials High-speed aseptic filling of prefilled syringes and liquid/lyophilised vials at the Maisons-Alfort facility in France, with up to 150 million prefilled syringe units per year capacity and up to 6 million vials per year including lyophilised formats. Serves pharma clients requiring large-scale European sterile injectables supply.
  • IV Bags and Plastic Ampoules (Blow-Fill-Seal) Manufacturing Manufacture of sterile IV bags from 50 mL to 5,000 mL and plastic ampoules using Blow-Fill-Seal (BFS) technology at the Halden facility in Norway, with IV bag batch sizes up to 15,000 L. Targets pharmaceutical clients needing high-volume sterile liquids and parenteral packaging.
  • Value-Added Medicines Development with HPAPI Expertise Specialised pharmaceutical development services at the Athens development centre covering Value-Added Medicines (VAMs), generic, and NCE development with HPAPI capabilities and EU GMP certification for handling controlled substances including clonazepam, phenobarbital, and fentanyl. Serves generic and specialty pharma companies needing differentiated formulations.
  • Tablets and Sterile Ampoules Manufacturing (Kawagoe) Manufacture of oral solid tablets (up to 2 billion annually) and sterile ampoules (up to 30 million units annually) with integrated visual inspection and packaging services at the Kawagoe facility in Japan, supported by PMDA certification and one of Japan's largest cold storage warehouses. Serves Japanese pharmaceutical clients requiring oral solid and sterile ampoule manufacturing with full service.
  • Sterile Liquids Ampoules and Suppositories Manufacturing (Livron) Sterile liquid ampoules and suppository manufacturing with over 100 years of operating experience at the Livron facility in France, handling over 100 molecules with integrated stability studies, narcotics handling, and analytical testing under EU GMP (ANSM, ANSES) and KFDA certification. Serves pharmaceutical clients requiring traditional European sterile ampoule and suppository supply.
  • Semi-Solids and Non-Sterile Liquids Manufacturing (Leipzig) Manufacture of semi-solid dosage forms (creams, gels, ointments, healing pastes) and non-sterile liquids (oral solutions, drops, suspensions, emulsions, disinfection products) at the Leipzig facility in Germany, with over 100 years of experience and EU GMP certification for human and veterinary medicinal products under the German Medicines Act.
  • Clinical and Commercial Small-Batch Sterile Manufacturing (Jura) GMP-certified clinical and commercial manufacturing of lyophilised and liquid sterile (bio)pharmaceuticals in small batches with no minimum lot size requirement at the Jura facility in Switzerland, supporting production from as little as 200-300 mL of API through commercial supply. Serves biotech, orphan-drug, and specialty pharma clients requiring low-volume lyophilised or liquid sterile production.
  • Automated Visual Inspection Services Automated and semi-automatic visual inspection for prefilled syringes (up to 600 syringes/minute) and vials (up to 100 vials/minute) ensuring consistent product quality at scale. Service is integrated with sterile manufacturing across facilities and is also offered for client-supplied product.
  • Pharmaceutical Packaging Services Complete primary and secondary pharmaceutical packaging solutions delivered in conjunction with manufacturing across the Adragos network. Supports prefilled syringe assembly, vial packaging, and finished product configuration.
  • Controlled Drugs Handling Services Specialised manufacturing and handling services for controlled substances and narcotics at facilities licensed for narcotics such as the Athens site (clonazepam, phenobarbital, fentanyl) and Livron's narcotics handling capability. Supports pharmaceutical clients requiring scheduled-drug production with full regulatory compliance.
  • Drug Stability Testing Services Comprehensive pharmaceutical stability testing services to establish product shelf-life and meet regulatory submission requirements across FDA, EMA, PMDA, and other authorities. Provided as integrated support alongside Adragos manufacturing and analytical development.
  • Cold Chain Management Services Temperature-controlled storage and distribution services for sensitive pharmaceutical products, leveraging cold-storage infrastructure such as the Kawagoe facility's large cold storage warehouse. Supports biotech and pharma products requiring strict temperature control across the supply chain.
  • Regulatory Affairs Services Regulatory affairs support across development, clinical, and commercial stages including eCTD-format documentation, submission preparation, and liaison with multi-regional authorities (FDA, EMA, PMDA, ANSM, Swissmedic, and others). Helps pharma clients navigate multi-market approval pathways.
  • Out Licensing Services Licensing-out services for pharmaceutical products and intellectual property developed at Adragos facilities, enabling partners to bring developed products into additional markets through structured licensing arrangements.

Quantifiable outcome

  • 150 million prefilled syringes per year capacity at Maisons-Alfort facility
  • +4 more outcomes

Companies that use Adragos Pharma

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Adragos Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Adragos Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered significant.

  • Towa Pharmaceutical (東和약품)significantStrategic or Co-development Partner · 1 January 2025Adragos Pharma Kawagoe signed a basic agreement for strategic collaboration with Towa Pharmaceutical, strengthening partnership for Japanese pharmaceutical manufacturing.
  • Colonis PharmasignificantStrategic or Co-development PartnerLong-standing partnership strengthened between Adragos Pharma and Colonis Pharma for pharmaceutical development and manufacturing collaboration.

Scale indicators10 records

Recent moves9 records

Expansion highlights5 records

Adragos Pharma competitors and assessment

Company assessment

Direct peers

  • Aenova Group: European CDMO offering oral solids, semi-solids and sterile liquids across multiple sites; comparable to Adragos' Leipzig, Livron and Maisons-Alfort footprint and similar mid-cap, multi-site profile.
  • Delpharm: European CDMO focused on sterile injectables, oral solids and semi-solids with multiple manufacturing sites; directly comparable size, geography and service mix to Adragos.
  • Rentschler Biopharma: European biopharma CDMO focused on complex biologics, cell and gene therapy and fill-finish — overlapping with Adragos' Athens HPAPI and Halden sterile capabilities for biotech clients.
  • Recipharm: Private European CDMO (EQT-owned) with broad sterile and oral solid capabilities across many sites; competes head-to-head with Adragos in fill-finish, oral solids and semi-solids for European pharma clients.
  • Siegfried Holding: Swiss-listed CDMO covering APIs through finished dosage forms including sterile and oral solids; comparable integrated offering and similar European base of operations.
  • Vetter Pharma: Family-owned German CDMO specializing in sterile injectables, prefilled syringes and lyophilized vials — directly overlapping with Adragos' Maisons-Alfort and Jura capabilities and targeting the same biotech and specialty-pharma clients.

Broad incumbents

  • Catalent (Novo Holdings): Global, multi-modality CDMO incumbent with large sterile injectable and oral solid capacity; competes with Adragos on large-scale biotech outsourcing deals where Adragos is one of many options.
  • Lonza Group: Swiss-listed global CDMO leader in biologics, small molecules and sterile manufacturing; sets the benchmark for scale and capability against which mid-caps like Adragos are benchmarked in RFPs.

Emerging players

  • Baccinex: Smaller European CDMO focused on sterile injectables and lyophilization; recently acquired by Adragos (Nov 2024), illustrating Adragos' M&A appetite and serving as a smaller-scale sterile injectable comparable.

Regional players

  • Fareva: Privately-held French-headquartered CDMO with sterile, semi-solid and oral solid manufacturing across Europe; comparable offering, particularly in France alongside Adragos' Livron and Maisons-Alfort sites.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Adragos Pharma social profiles

Digital presence

Adragos Pharma compliance and trust

Trust signal

Compliance9 records

Adragos Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adragos Pharma leadership team

Management profile

Number of profiles

Profiles15 records

Adragos Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Adragos Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adragos Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adragos Pharma

What does Adragos Pharma do?

Adragos Pharma is a global Contract Development and Manufacturing Organization (CDMO) providing end-to-end pharmaceutical services spanning drug development, clinical manufacturing, and commercial manufacturing. Its offering covers formulation, analytical, and clinical development including HPAPI expertise, GMP-compliant clinical trial manufacturing, and large-scale commercial production of sterile liquids (prefilled syringes, vials, ampoules, IV bags), non-sterile liquids, oral solids, semi-solids, and suppositories, complemented by visual inspection, packaging, cold chain, regulatory, and out-licensing services across seven facilities in Europe and Japan.

Is Adragos Pharma a public or private company?

Adragos Pharma is a private company. It is classified as corporate owned and is currently operating.

When was Adragos Pharma founded?

Adragos Pharma was founded in 2020. It employs 251 to 500 people.

Where is Adragos Pharma based?

Adragos Pharma is headquartered in Munich, Germany, in the Europe region.

How does Adragos Pharma make money?

Four revenue lines are on record. Contract Development Services are the primary driver. The others are clinical Manufacturing Services, commercial Manufacturing Services and integrated Services.

Who are Adragos Pharma's main competitors?

Direct peers on record are Aenova Group, Delpharm, Rentschler Biopharma, Recipharm, Siegfried Holding and Vetter Pharma. Broad incumbents are Catalent (Novo Holdings) and Lonza Group. Baccinex is listed as an emerging player. Fareva is listed as a regional player.

Does Adragos Pharma have an API?

No public API is recorded for Adragos Pharma.

What industry is Adragos Pharma in?

Adragos Pharma's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceBiologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacityThe growing demand for biologics, biosimilars, GLP-1 drugs, and advanced therapies is driving contract manufacturing organizations (CMOs and CDMOs) to significantly expand their sterile fill-finish, lyophilization, and prefilled syringe capabilities. PCI Pharma Services announced a $1 billion global expansion program in May to add sterile fill/finish and drug-device combination capabilities at U.S. sites, while other CMOs/CDMOs including Adragos Pharma and BioConnection are also scaling up operations across Europe and Japan. The global prefilled syringe market is projected to expand from $9.4 billion in 2026 to $20.3 billion by 2035, driven by increasing chronic illness prevalence and self-injection trends.GlobeNewswireBlow-Fill-Seal Technology Market Report 2026The blow-fill-seal (BFS) technology market is projected to grow from $3.94 billion in 2025 to $4.41 billion in 2026, reaching $6.95 billion by 2030, driven by increasing demand for sterile pharmaceutical packaging and injectable drug production. Key growth factors include the expansion of biologics and vaccine manufacturing, regulatory focus on aseptic processing, and adoption of automated filling technologies, with North America holding the largest regional market share. Strategic developments include Adragos Pharma's acquisition of a BFS facility in Halden, Norway, and Brevetti Angela Srl's 2024 launch of the SYFPAC DUO BFS platform, though the market faces headwinds from tariffs on essential BFS components.GlobeNewswireBlow-Fill-Seal Technology Market Report 2026Research and Markets published its Blow-Fill-Seal Technology Market Report 2026, projecting the market to grow from $3.94 billion in 2025 to $4.41 billion in 2026 at an 11.8% CAGR, reaching $6.95 billion by 2030. The growth is driven by rising demand for sterile pharmaceutical packaging, increased biologics and vaccine production, and regulatory emphasis on aseptic manufacturing, with North America holding 54.8% of global pharmaceutical sales. Notable strategic moves include Adragos Pharma's acquisition of a BFS facility in Halden, Norway, and Brevetti Angela Srl's launch of the SYFPAC DUO BFS platform, while the market faces challenges from tariffs impacting essential BFS component costs in North America and Europe.InvestorsinhealthcareGermany: Adragos Pharma appoints Kostas Rengis as CEOAdragos Pharma, a Germany-based CDMO, appointed Kostas Rengis as CEO, succeeding founder and CEO Andreas Raabe. Raabe will continue in a non-executive role. The appointment marks a leadership change at the company.Pharmaceutical TechnologyPharma’s manufacturing reconfigurations provide CDMOs with expansion opportunitiesA cluster of three pharma-to-CDMO facility deals emerged between March and April 2026, reversing an eight-month period with only two such transactions. Samsung Biologics acquired GSK's Rockville, US facility, giving the South Korean CDMO its first US manufacturing presence and adding 60,000L of drug substance capacity. The deals included Bristol Myers Squibb selling a Phoenix injectables plant to Rois and Adragos Pharma acquiring a Sanofi sterile fill-finish site in France, reflecting a broader industry shift as pharmaceutical companies retool manufacturing footprints amid onshore US production pressures.openPR.comNon-PVC IV Bags Market Overview: Major Segments, Strategic Developments, and Leading CompaniesThe non-PVC IV bags market is projected to reach $3.8 billion by 2030, growing at a compound annual growth rate of 10.8%, driven by demand for eco-friendly medical products and stricter regulatory scrutiny on material safety. In November 2023, Prange Group and Adragos Pharma acquired Fresenius Kabi's sterile pharmaceutical production facility to expand manufacturing across Europe, North America, and Japan, with Fresenius Kabi continuing to supply products under a long-term agreement. In February 2024, UK-based Innovia Films launched RayoFloat white APO, a polyolefin shrink film incorporating up to 20% post-industrial recycled content for light-sensitive medical packaging.StartseiteAdragos Pharma Completes Acquisition of Sanofi’s Sterile Fill-Finish Site in FranceAdragos Pharma has completed the acquisition of Sanofi’s sterile fill-finish site in Maisons-Alfort, France, marking a significant expansion of its European pharmaceutical manufacturing network. The facility is one of Europe’s largest for sterile injectables, with industrial-scale capacity for pre-filled syringes, liquid and lyophilized vials, and will add high-volume manufacturing capabilities to Adragos’ existing operations in Switzerland and France. The transaction terms were not disclosed, and all site employees are joining Adragos Pharma, preserving operational continuity at the facility.Towards HealthcareAseptic Fill Finish Manufacturing Market Ascends $14.01 Bn by 2034The global aseptic fill finish manufacturing market is projected to grow from USD 5.94 billion in 2024 to USD 14.01 billion by 2034, driven by rising demand for biologics and advancements in sterile manufacturing technology. Key industry participants such as Recipharm, Adragos Pharma, and Symbiosis Pharmaceutical Services are expanding capacities through new facilities and acquisitions to meet this growth. The sector is also seeing increased adoption of AI and single-use technologies to enhance efficiency and maintain sterility.Adragos-PharmaUnderstanding cGMP: Key Insights for Effective Manufacturing PracticesThe article provides a comprehensive overview of current Good Manufacturing Practice (cGMP) regulations, detailing their definition, regulatory framework enforced by agencies like the FDA, and certification processes for pharmaceutical and medical device manufacturers. It outlines key operational requirements including the 'Five Ps' framework—People, Premises, Processes, Products, and Procedures—to ensure product quality, safety, and compliance with global standards. The piece concludes by highlighting Adragos Pharma's commitment to these rigorous manufacturing practices to maintain trust and operational excellence.Adragos-Pharma3 CDMO Trends Shaping Pharma in 2025: Insights from Our CCOAdragos Pharma's Chief Commercial Officer, Henny Zijlstra, contributed insights to a Contract Pharma roundtable identifying three key trends for CDMOs in 2025: network consolidation through mergers and acquisitions, client-centric digitalization, and the continued onshoring of projects. The article highlights these strategic shifts as critical areas for pharmaceutical development and manufacturing companies to address in the coming year.